NO20073334L - Nanopartikulaert benzotiofenformuleringer - Google Patents
Nanopartikulaert benzotiofenformuleringerInfo
- Publication number
- NO20073334L NO20073334L NO20073334A NO20073334A NO20073334L NO 20073334 L NO20073334 L NO 20073334L NO 20073334 A NO20073334 A NO 20073334A NO 20073334 A NO20073334 A NO 20073334A NO 20073334 L NO20073334 L NO 20073334L
- Authority
- NO
- Norway
- Prior art keywords
- nanoparticulate benzothiophene
- compositions
- raloxifene hydrochloride
- nanoparticle form
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63300304P | 2004-12-03 | 2004-12-03 | |
PCT/US2005/043707 WO2006060698A1 (fr) | 2004-12-03 | 2005-12-02 | Formulations nanoparticulaires de benzothiophene |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073334L true NO20073334L (no) | 2007-08-21 |
Family
ID=36168420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073334A NO20073334L (no) | 2004-12-03 | 2007-06-28 | Nanopartikulaert benzotiofenformuleringer |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060159628A1 (fr) |
EP (1) | EP1827430A1 (fr) |
JP (1) | JP2008521931A (fr) |
KR (1) | KR20070098834A (fr) |
CN (1) | CN101365449B (fr) |
AU (1) | AU2005311731B2 (fr) |
BR (1) | BRPI0518772A2 (fr) |
CA (1) | CA2589824A1 (fr) |
EA (1) | EA200701202A1 (fr) |
IL (1) | IL183549A0 (fr) |
NO (1) | NO20073334L (fr) |
NZ (1) | NZ556009A (fr) |
UA (1) | UA89513C2 (fr) |
WO (1) | WO2006060698A1 (fr) |
ZA (1) | ZA200704528B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090015994A (ko) | 2006-05-30 | 2009-02-12 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 포사코나졸 제제 |
CA2653384C (fr) | 2006-06-30 | 2017-03-14 | Iceutica Pty Ltd | Procedes de preparation de composes biologiquement actifs sous forme de nanoparticules |
WO2008005509A2 (fr) * | 2006-07-06 | 2008-01-10 | Massachusetts Institute Of Technology | Procédés et compositions destinés à modifier des surfaces biologiques |
TW200820991A (en) * | 2006-07-10 | 2008-05-16 | Elan Pharma Int Ltd | Nanoparticulate sorafenib formulations |
EP2043623A4 (fr) * | 2006-07-12 | 2013-03-20 | Elan Pharma Int Ltd | Formulations de nanoparticules de modafinil |
WO2009117410A2 (fr) * | 2008-03-17 | 2009-09-24 | Board Of Regents, The University Of Texas System | Formation de particules nanostructurées de médicaments médiocrement solubles dans l'eau et récupération par des techniques mécaniques |
WO2009146097A1 (fr) * | 2008-04-02 | 2009-12-03 | Dr. Reddy's Laboratories Ltd. | Formulations pharmaceutiques de raloxifène |
NZ595987A (en) | 2009-04-24 | 2014-02-28 | Iceutica Pty Ltd | A novel formulation of diclofenac |
BRPI1014275B8 (pt) | 2009-04-24 | 2021-05-25 | Iceutica Pty Ltd | composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos |
AU2010254180B2 (en) | 2009-05-27 | 2015-08-27 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
WO2011146583A2 (fr) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Formulations de cinacalcet nanoparticulaire |
US8900635B2 (en) | 2010-11-15 | 2014-12-02 | Humanetics Corporation | Nanoparticle isoflavone compositions and methods of making and using the same |
EP2468258A1 (fr) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Procédé de préparation d'une composition pharmaceutique comportant un ingrédient actif pharmaceutiquement faiblement soluble |
WO2013006761A2 (fr) | 2011-07-07 | 2013-01-10 | Arqule, Inc. | Formulations de pyrroloquinolinyl-pyrrolidine-2,5-dione et procédés de préparation et d'utilisation associés |
KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
EP2863897B1 (fr) * | 2012-06-21 | 2019-06-19 | Phosphorex Inc. | Nanoparticules d'indirubine, leurs dérivés et leurs procédés de fabrication et d'utilisation |
AU2014226290B2 (en) * | 2013-03-04 | 2018-11-15 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
BR112015026298A8 (pt) * | 2013-04-19 | 2019-12-24 | Univ Saskatchewan | veículo de dispensação para a dispensação de um inibidor da aromatase |
KR101741344B1 (ko) | 2013-06-28 | 2017-05-29 | 렉산 파마슈티컬스, 인코포레이티드 | 피페라진 화합물의 나노미립자 조성물 및 제제 |
WO2015071841A1 (fr) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci |
US9084726B2 (en) * | 2013-11-26 | 2015-07-21 | Humanetics Corporation | Suspension compositions of physiologically active phenolic compounds and methods of making and using the same |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
KR20200021451A (ko) * | 2017-04-07 | 2020-02-28 | 엠에이에이 래보러토리스, 인코포레이티드 | 치료제의 용해도 및 생체이용률을 향상시키는 방법 |
CN109925314B (zh) * | 2018-11-15 | 2022-02-22 | 沈阳药科大学 | 一种盐酸雷洛昔芬磷脂复合物固体分散体及其制备 |
WO2021099966A2 (fr) * | 2019-11-19 | 2021-05-27 | Nibn, The National Institute For Biotechnology In The Negev Ltd. | Nouveaux dérivés de benzothiophène et leur utilisation pour stimuler le renouvellement mitochondrial |
KR102351931B1 (ko) * | 2020-12-30 | 2022-01-17 | 주식회사유한양행 | 라록시펜 염산염을 포함하는 약학 조성물 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
US5458876A (en) * | 1988-12-21 | 1995-10-17 | Haarman & Reimer Corp. | Control of microbial growth with lantibiotic/lysozyme formulations |
ES2089011T3 (es) * | 1989-02-17 | 1996-10-01 | Liposome Co Inc | Excipiente lipidico de administracion nasal y aplicacion topica. |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
JPH06511481A (ja) * | 1991-07-05 | 1994-12-22 | ユニバーシティ オブ ロチェスター | 気泡を取り込む超微小非凝集多孔質粒子 |
US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5349957A (en) * | 1992-12-02 | 1994-09-27 | Sterling Winthrop Inc. | Preparation and magnetic properties of very small magnetite-dextran particles |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) * | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
US5433196A (en) * | 1993-06-02 | 1995-07-18 | The Board Of Trustees Of The University Of Illinois | Oxygen-17 NMR spectroscopy and imaging in the human |
US5827845A (en) * | 1993-09-29 | 1998-10-27 | Meiji Seika Kaisha, Ltd. | Cephalosporin derivative |
US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5478847A (en) * | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
WO1996025918A1 (fr) * | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols contenant des dispersions de nanoparticules |
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5643552A (en) * | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
US5472683A (en) * | 1995-03-09 | 1995-12-05 | Eastman Kodak Company | Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
US5573749A (en) * | 1995-03-09 | 1996-11-12 | Nano Systems L.L.C. | Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
US5573750A (en) * | 1995-05-22 | 1996-11-12 | Nanosystems L.L.C. | Diagnostic imaging x-ray contrast agents |
US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
KR0155639B1 (ko) * | 1995-10-04 | 1998-11-16 | 김광호 | 비엔씨/디-서브 자동선택회로 |
US6458811B1 (en) * | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1998035666A1 (fr) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Preparation de pastilles de naproxene nanoparticulaire |
US6153225A (en) * | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
US6431478B1 (en) * | 1999-06-01 | 2002-08-13 | Elan Pharma International Limited | Small-scale mill and method thereof |
US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DK1313564T3 (da) * | 2000-04-26 | 2010-04-06 | Elan Pharma Int Ltd | Apparat til hygienisk våd formaling |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
EP1392441B1 (fr) * | 2001-06-05 | 2008-07-23 | Elan Pharma International Limited | Systeme et procede de broyage de matieres |
ATE371442T1 (de) * | 2001-10-12 | 2007-09-15 | Elan Pharma Int Ltd | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
JP4533134B2 (ja) * | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル,リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
AU2003261167A1 (en) * | 2002-07-16 | 2004-02-02 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
DE60327225D1 (de) * | 2002-08-20 | 2009-05-28 | Bristol Myers Squibb Co | Aripiprazol-komplex-formulierung und verfahren |
JP4878839B2 (ja) * | 2002-09-11 | 2012-02-15 | エラン ファーマ インターナショナル,リミティド | ゲル安定化ナノパーティクル活性物質組成物 |
AU2003275329B2 (en) * | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
JP2006501936A (ja) * | 2002-10-04 | 2006-01-19 | エラン ファーマ インターナショナル,リミティド | 固体ナノ粒子活性薬剤のガンマ線照射 |
US7879360B2 (en) * | 2003-11-05 | 2011-02-01 | Elan Pharma International, Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
-
2005
- 2005-02-12 UA UAA200707397A patent/UA89513C2/uk unknown
- 2005-12-02 KR KR1020077014836A patent/KR20070098834A/ko not_active Application Discontinuation
- 2005-12-02 NZ NZ556009A patent/NZ556009A/en not_active IP Right Cessation
- 2005-12-02 CN CN2005800475550A patent/CN101365449B/zh not_active Expired - Fee Related
- 2005-12-02 EP EP05852820A patent/EP1827430A1/fr not_active Withdrawn
- 2005-12-02 BR BRPI0518772-9A patent/BRPI0518772A2/pt not_active IP Right Cessation
- 2005-12-02 WO PCT/US2005/043707 patent/WO2006060698A1/fr active Application Filing
- 2005-12-02 EA EA200701202A patent/EA200701202A1/ru unknown
- 2005-12-02 CA CA002589824A patent/CA2589824A1/fr not_active Abandoned
- 2005-12-02 JP JP2007544559A patent/JP2008521931A/ja active Pending
- 2005-12-02 AU AU2005311731A patent/AU2005311731B2/en not_active Ceased
- 2005-12-02 US US11/292,314 patent/US20060159628A1/en not_active Abandoned
-
2007
- 2007-05-30 IL IL183549A patent/IL183549A0/en unknown
- 2007-05-31 ZA ZA200704528A patent/ZA200704528B/xx unknown
- 2007-06-28 NO NO20073334A patent/NO20073334L/no not_active Application Discontinuation
-
2008
- 2008-09-25 US US12/232,895 patent/US20090035366A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090035366A1 (en) | 2009-02-05 |
EP1827430A1 (fr) | 2007-09-05 |
CN101365449B (zh) | 2011-11-09 |
WO2006060698A1 (fr) | 2006-06-08 |
UA89513C2 (uk) | 2010-02-10 |
AU2005311731A1 (en) | 2006-06-08 |
NZ556009A (en) | 2009-02-28 |
AU2005311731B2 (en) | 2010-12-23 |
ZA200704528B (en) | 2008-09-25 |
JP2008521931A (ja) | 2008-06-26 |
EA200701202A1 (ru) | 2008-04-28 |
US20060159628A1 (en) | 2006-07-20 |
IL183549A0 (en) | 2007-09-20 |
CN101365449A (zh) | 2009-02-11 |
CA2589824A1 (fr) | 2006-06-08 |
BRPI0518772A2 (pt) | 2008-12-09 |
KR20070098834A (ko) | 2007-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073334L (no) | Nanopartikulaert benzotiofenformuleringer | |
NO20073559L (no) | Nanopartiklulaere tacrolimus-formuleringer | |
NO2023022I1 (no) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
CY1118113T1 (el) | Υψηλου βαθμου καθαροτητας 2-[4-(3- και 2-φθοροβενζυλοξυ)βενζυλαμινο]προπαναμιδια για χρηση ως φαρμακα και φαρμακοτεχνικες μορφες που περιεχουν αυτα | |
JP2009531457A5 (fr) | ||
EA200702638A1 (ru) | Стабильная композиция (рецептура) с наночастицами ацетаминофена | |
UA84318C2 (ru) | Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе | |
SG170047A1 (en) | Nanoparticulate posaconazole formulations | |
WO2006110809A3 (fr) | Formulations inhibitrices de lipase nanoparticulaire | |
MX2009005727A (es) | Nanoparticulas de entidad anfifilica. | |
IL189601A (en) | Paclitaxel / albumin nanoparticles containing adatate and sucrose | |
WO2007066150A3 (fr) | Administration de principes actifs par voie transdermique pour l'obtention d'un effet systemique | |
CR7432A (es) | Amidas sustituidas activas del receptor de canabinoide-1 | |
NO20076691L (no) | Nanopartikulaere imatinib-mesylatformuleringer | |
EA200701357A1 (ru) | Композиции и способы применения модулятора рецептора 5ht | |
TW200733961A (en) | Diaryl urea for treating pulmonary hypertension | |
PT1401501E (pt) | Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo | |
DK1768748T4 (da) | Sammensætninger omfattende strontium og vitamin D og anvendelser deraf | |
RU2007137846A (ru) | Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц | |
JP2008538751A5 (fr) | ||
EA200702595A1 (ru) | Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов | |
ATE446742T1 (de) | Nanopartikuläre ebastinformulierungen | |
EA200601596A1 (ru) | Улучшенный состав 6-меркаптопурина | |
ATE365735T1 (de) | Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel | |
PL1979521T3 (pl) | Nowy sposób impregnowania powierzchni tekstylnych |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |